Filtered By:
Cancer: Colorectal Cancer
Education: Study
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 283 results found since Jan 2013.
Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study
CONCLUSIONS: Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II-III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.PMID:36240841 | DOI:10.6004/jnccn.2022.7042
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Shing Fung Lee Pui Lam Yip Balamurugan A Vellayappan Cheng Ean Chee Lea Choung Wong Eric Yuk-Fai Wan Esther Wai-Yin Chan Chak-Fei Lee Francis Ann-Shing Lee Miguel Angel Luque-Fernandez Source Type: research
Short bevacizumab infusion as an effective and safe treatment for colorectal cancer
Mol Clin Oncol. 2022 Jul 27;17(3):139. doi: 10.3892/mco.2022.2572. eCollection 2022 Sep.ABSTRACTBevacizumab is a humanized monoclonal antibody that contains <10% murine protein. To prevent infusion-related hypersensitivity reactions (HSRs), the initial bevacizumab infusion is delivered for 90 min, the second for 60 min and subsequent doses for 30 min. Several previous studies have shown that short bevacizumab infusions are safe and do not result in severe HSRs in patients with colorectal, lung, ovarian and brain cancer. However, the efficacy of short bevacizumab infusions for colorectal cancer management remains unclear...
Source: Clinical Colorectal Cancer - August 11, 2022 Category: Cancer & Oncology Authors: Koichi Taira Shunsuke Okazaki Kohei Akiyoshi Hirohisa Machida Tetsuro Ikeya Akie Kimura Akinobu Nakata Yuji Nadatani Masaki Ohminami Shusei Fukunaga Koji Otani Shuhei Hosomi Fumio Tanaka Noriko Kamata Yasuaki Nagami Yasuhiro Fujiwara Source Type: research
